Table 3.

Change in brachial artery flow-mediated dilation with ascorbic acid infusion in participants with autosomal dominant polycystic kidney disease and control participants

VariableFMDBA with Saline InfusionFMDBA with Ascorbic Acid InfusionChange in FMDBA
ADPKD, n=527.7±4.59.4±5.21.72 (0.80 to 2.63)
Control, n=1910.8±4.710.6±5.4−0.20 (−1.24 to 0.84)
  • Data are mean±SD or mean (95% confidence interval). P interaction (group × condition) =0.02. FMDBA, brachial artery flow-mediated dilation; ADPKD, autosomal dominant polycystic kidney disease.